Up the Ladder: Latest Executive Appointments and Departures in the Business World

Prometu invites its readers to share news about hires, promotions, and personnel movements within their organizations. The goal is to keep the community informed about changes and developments in the business world. This initiative aims to be a meeting point for the dissemination of relevant information about talent and the evolution of companies.

The section is updated weekly, offering a detailed view of changes in leadership and new incorporations. The participation of readers is essential to keep this section updated and relevant, thus fostering a collaborative information network.

Averna Therapeutics has appointed Robert Mabry as its new chief scientific officer. Mabry brings extensive experience to the role, having previously served as chief executive officer at Hillstar Bio. Prior to Hillstar Bio, Mabry was global head of biologics at Takeda Pharmaceuticals.

This appointment represents a strategic move for Averna Therapeutics, which seeks to strengthen its leadership in the field of scientific research and development. Mabry's experience in different roles and companies provides him with a comprehensive perspective to lead innovation within the company.

Before joining Averna Therapeutics, Robert Mabry played a crucial role at Hillstar Bio as chief executive officer, demonstrating his ability to lead and manage operations at the executive level. His previous experience at Takeda Pharmaceuticals, where he was global head of biologics, provided him with a solid foundation in the development and management of biological products.

These previous roles showcase his ability to adapt to different environments and his deep knowledge of the pharmaceutical industry. The combination of these experiences makes Mabry a valuable asset to Averna Therapeutics, bringing a strategic perspective and a focus on scientific innovation.